Sanofi Eyes Blockbuster Potential with 12 Pipeline Assets, Projects EUR 10 Billion in Annual Sales by 2030
Sanofi (NASDAQ: SNY) this week outlined its growth potential for the 2024 to 2025 period,...
J&J
J&J Forecasts 5-7% CAGR Through 2030, Driven by Innovative Medicine and Device Growth
Johnson & Johnson (J&J; NYSE: JNJ) has presented an update on its business strategy, pipeline,...
Johnson & Johnson Acquires Laminar for $400 Million to Enhance Heart Rhythm Solutions
Johnson & Johnson (J&J; NYSE: JNJ) has finalized the acquisition of medical device manufacturer Laminar...
Janssen Submits Indication Extension Application to FDA for Rybrevant in NSCLC Treatment
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has filed an indication extension...
Janssen Presents Real-World Data on Tremfya’s Efficacy in Treatment-Resistant Psoriatic Arthritis
Johnson & Johnson’s (J&J; NYSE: JNJ) pharmaceutical unit, Janssen, has presented real-world efficacy data for...
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...
Janssen’s Nipocalimab Shows Promising Results in Phase II Rheumatoid Arthritis Trial
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has announced the results of...
GSK Acquires Global Rights to Janssen’s Hepatitis B Antiviral JNJ-3989 in $1 Billion Deal
GlaxoSmithKline (GSK; NYSE: GSK) has announced the acquisition of global rights to the hepatitis B...
GSK’s ViiV Healthcare Secures NMPA Approval for Vocabria in HIV-1 Treatment
UK pharmaceutical giant GlaxoSmithKline (GSK, NYSE: GSK) has announced that its HIV joint venture, ViiV...
J&J MedTech Partners with CED Medical for Neurointerventional Solutions
Johnson & Johnson MedTech’s (J&J, NYSE: JNJ) Shanghai-based subsidiary, Johnson Johnson Medical Equipment Co., Ltd,...
Janssen’s TAR-200 Shows High Complete Response Rate in Bladder Cancer Study
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has published data from a Phase IIb...
J&J Reports Strong Q3 2023 Sales Growth Amid Diverse Business Performance
Johnson & Johnson (J&J; NYSE: JNJ) has released its Q3 2023 report, revealing impressive global...
J&J’s Cetrelimab and TAR-200 Gain Tacit Approvals for Bladder Cancer Trials
The Center for Drug Evaluation (CDE) website has indicated that Johnson & Johnson (J&J; NYSE:...
Janssen Unveils Promising Clinical Data on IL-23 Blockers for Psoriasis
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) is showcasing new clinical data...
J&J’s Janssen Reports Favorable Spravato Data in Late-Stage TRD Trial
Johnson & Johnson’s (J&J; NYSE: JNJ) subsidiary, Janssen, has presented tolerability and efficacy data from...
Janssen and Sanofi Partner for Development of First-in-Class E. coli Vaccine
The Janssen unit of Johnson & Johnson (J&J; NYSE: JNJ) has entered into a strategic...
J&J and HHS Expand Public Health Initiative with Asha Therapeutics
Johnson & Johnson (J&J; NYSE: JNJ) and the US Department of Health and Human Services...
South Africa’s Competition Commission Investigates J&J for MDR-TB Drug Pricing and Evergreening
The Competition Commission of South Africa has announced an investigation into Johnson & Johnson (J&J;...
J&J Rebrands Pharmaceutical and MedTech Segments Post-Kenvue Separation
Following the completion of its consumer healthcare unit separation as Kenvue (NYSE: KVUE) last month,...
AbbVie’s Skyrizi Outperforms Janssen’s Stelara in Phase III Crohn’s Disease Trial
AbbVie (NYSE: ABBV) has announced early data from a Phase III trial that compared the...